Zhuhai Sailong Pharmaceutical Co Ltd (002898) - Total Assets
Based on the latest financial reports, Zhuhai Sailong Pharmaceutical Co Ltd (002898) holds total assets worth CN¥797.54 Million CNY (≈ $116.71 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 002898 net assets for net asset value and shareholders' equity analysis.
Zhuhai Sailong Pharmaceutical Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Zhuhai Sailong Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Zhuhai Sailong Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhuhai Sailong Pharmaceutical Co Ltd's total assets of CN¥797.54 Million consist of 30.9% current assets and 69.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.0% |
| Accounts Receivable | CN¥102.68 Million | 12.7% |
| Inventory | CN¥94.08 Million | 11.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥123.81 Million | 15.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Zhuhai Sailong Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 002898 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhuhai Sailong Pharmaceutical Co Ltd's current assets represent 30.9% of total assets in 2024, a decrease from 71.5% in 2013.
- Cash Position: Cash and equivalents constituted 6.0% of total assets in 2024, down from 45.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 2.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 15.3% of total assets.
Zhuhai Sailong Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Zhuhai Sailong Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $1.30 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.48 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Zhuhai Sailong Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.82 | 1.10 | 1.28 |
| Quick Ratio | 0.50 | 0.75 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-55.18 Million | CN¥25.90 Million | CN¥52.65 Million |
Zhuhai Sailong Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhuhai Sailong Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.31 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -0.7% |
| Total Assets | CN¥808.22 Million |
| Market Capitalization | $213.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhuhai Sailong Pharmaceutical Co Ltd's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Zhuhai Sailong Pharmaceutical Co Ltd's assets decreased by 0.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Zhuhai Sailong Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total assets of Zhuhai Sailong Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥808.22 Million ≈ $118.27 Million |
-0.69% |
| 2023-12-31 | CN¥813.84 Million ≈ $119.09 Million |
-4.03% |
| 2022-12-31 | CN¥847.99 Million ≈ $124.09 Million |
-3.94% |
| 2021-12-31 | CN¥882.78 Million ≈ $129.18 Million |
+8.46% |
| 2020-12-31 | CN¥813.96 Million ≈ $119.11 Million |
-2.63% |
| 2019-12-31 | CN¥835.98 Million ≈ $122.33 Million |
+10.60% |
| 2018-12-31 | CN¥755.84 Million ≈ $110.60 Million |
+5.69% |
| 2017-12-31 | CN¥715.13 Million ≈ $104.65 Million |
+133.97% |
| 2016-12-31 | CN¥305.66 Million ≈ $44.73 Million |
+15.46% |
| 2015-12-31 | CN¥264.73 Million ≈ $38.74 Million |
+39.71% |
| 2014-12-31 | CN¥189.48 Million ≈ $27.73 Million |
+1.65% |
| 2013-12-31 | CN¥186.41 Million ≈ $27.28 Million |
-- |
About Zhuhai Sailong Pharmaceutical Co Ltd
Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pan… Read more